1 / 23

Pregabalin An Overview

Pregabalin An Overview. Dr. Shaun Greene. What is Pregabalin?. G abapentinoid used for the Rx of epilepsy + neuropathic pain Trade name in Australia = Lyrica  Analgesic, anticonvulsant, anxiolytic, sleep modulator Pharmaceutical Benefits Scheme (PBS):

neron
Télécharger la présentation

Pregabalin An Overview

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PregabalinAn Overview Dr. Shaun Greene

  2. What is Pregabalin? • Gabapentinoid used for the Rx of epilepsy + neuropathic pain • Trade name in Australia = Lyrica • Analgesic, anticonvulsant, anxiolytic, sleep modulator • Pharmaceutical Benefits Scheme (PBS): Refractory neuropathic pain not controlled by other drugs

  3. Gabapentinoids: derivatives of GABA (gamma-aminobutyric acid)

  4. Pharmacodynamics • What does Pregabalin do to the body? • Binds to neuronal voltage gated calcium channels (VGCCs) • Inhibits calcium conductance through VGCCs • Increases the expression of L-glutamic acid decarboxylase (GAD) • GAD is an enzyme utilised to synthesize GABA • Pregabalin does not bind to GABA receptors or form GABA

  5. Pharmacokinetics • What does the body do to Pregabalin? • Active absorption from gastrointestinal tract (no saturation) • 90% bioavailable, food may delay absorption • Active transport across the blood-brain-barrier into CNS • 98% eliminated unchanged in urine • Half-life 6-7 hours

  6. History: International • First synthesised in 1990, Northwestern University, Illinois USA • Created originally as an anticonvulsant • Approved for use by FDA and European Union in 2004 • Epilepsy, diabetic neuropathy, post herpetic neuralgia

  7. History: Australia • 2004: Therapeutic Goods Administration • Treatment of neuropathic pain in adults and as adjunctive therapy in adults with partial seizures with or without secondary generalisation • 2011: Pharmaceutical Benefits Advisory Committee (PBAC) • Reject: Initial and continuing treatment of neuropathic pain • Uncertain cost effectiveness

  8. History: Australia • 2012: Pharmaceutical Benefits Advisory Committee (PBAC) • The PBAC recommended the listing of pregabalin on the PBS as an Authority Required (Streamlined) benefit for the treatment of refractory neuropathic pain not controlled by other drugs on the basis of acceptable cost-effectiveness compared with placebo in patients dissatisfied with their current pain relief.

  9. Indications for use in Australia

  10. Prescribing Information • Tablet strengths: 25mg, 75mg, 150mg, 300 mg • PBS streamlined - 56 tablets - General patient charge $40.30

  11. Evidence for Benefit: Neuropathic pain • Moderate-quality evidence shows pregabalin 300-600 mg daily has an important effect on pain in some people with moderate or severe neuropathic pain after shingles, or due to diabetes.

  12. Evidence for Benefit: Neuropathic pain • Moderate-quality evidence shows pregabalin 300-600 mg daily has an important effect on pain in some people with moderate or severe neuropathic pain after shingles, or due to diabetes.

  13. Evidence for Benefit: Neuropathic pain • Helpful for some people with chronic neuropathic pain • Not possible to know beforehand who will benefit / who won’t • Current knowledge suggests that a short course of treatment (perhaps four weeks) is the best way of telling • Some people will derive substantial benefit with pregabalin; more will have moderate benefit, but many will have no benefit.

  14. Evidence for Benefit: Fibromyalgia • Cochrane: High quality evidence that pregabalin at daily doses of 300-600 mg produces a large fall in pain in about 1 in 10 people with moderate or severe pain from fibromyalgia. Pain reduction comes with improvements in other symptoms, in quality of life, and in ability to function. • Number needed to treat (NNT) = 11

  15. Evidence for Benefit: Generalised Anxiety Disorder • Pregabalin superior to placebo for amelioration of symptoms • The anticonvulsants gabapentin and pregabalin showed moderate-quality evidence of a clinical response

  16. Evidence for Benefit: Other Conditions • Acute pain or chronic non-neuropathic pain: no evidence

  17. Adverse Effects with Therapeutic Doses • Reported by at least 3% of patients:

  18. Potential for Misuse Evidence suggests gabapentinoids possess potential for abuse, particularly in individuals with a history of opioid abuse, and reports of such abuse are increasingly being documented.

  19. Effects in Overdose •  CNS: dizziness, agitation, delirium, headache, myoclonus, coma, tremor, fasciculations, ataxia • Other: ECG abnormalities, GI upset, kidney injury, cardiac failure • Care is supportive • Death is unlikely following lone Pregabalin OD

  20. Lethality in Overdose? • Frequently found with opioids, benzodiazepines, antidepressants • Less lethal than opioids and tricyclic antidepressants taken alone • Aust: • UK:

  21. VPIC Pregabalin Enquiries

  22. Summary: Pregabalin • Gabapentinoid approved for Rx of neuropathic pain + epilepsy • Increasing prescription rates in Australia • Moderately effective for a minority of patients • Carries significant risk of misuse • Increasing involvement in multi-drug fatal ODs

More Related